Home » About Us » Management Team
Management Team

The Source...

        Of Your Technology Solutions

Our Team

Our team combines seasoned managers, leading edge computer systems architects, and medical practitioners.  The ability to synthesize these backgrounds into solid, forward-looking solutions gives PharmaVigilant a unique advantage in building end to end solutions that address the issues facing R&D, both now and in the future. 


James DeSanti: Chief Executive Officer

James has over 25 years experience in the pharmaceutical and software industries.  He started his career at Johnson and Johnson, involved in Sales & Marketing (product development, and launches). He was later named President of Walsh Americas, with operations in the USA, Canada, and Brazil.   James has extensive international experience, starting and managing companies in North America, Europe, and South America.  He has been involved in over 400 clinical trials and nine clinical technology transfers in the pharmaceutical, biotech, and medical device industries.

Patty Giencke: Chief Architect

Patty was a co-founder of Software.com/Open Wave Technologies and an original architect of Phase Forward. With nearly 25 years in software design, she has extensive experience in user interface design, system architecture and database design for very large mission critical systems. Her 10+ years working with the pharmaceutical industry has given her a deep appreciation of the needs of sponsors and how best to make software work for them. She is published both in software topics and in how to design trials for the electronic world.

Drew Millecchia: Chief Technology Officer

Drew leads the company's global technology design, strategy and deployments. He has over 15 years of technology experience, 11 of which have been in the clinical software industry. Since 2002 he has architected and developed state of the art products that have become an enterprise Clinical Trial Management System for pharmaceutical clinical trials. Drew's products have been used in over 100 Phase 1-4 trials across 41 countries nationwide and have grown to be the only interoperable software suite in the industry.

Contact Us for
Additional Information

General Inquiries Contact Us here